Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study she and colleagues conducted to assess the impact of social determinants of health in the context of germline genetic testing for triple-negative breast cancer in the community oncology setting.
Transcript
Which social determinants of health were most impactful on germline genetic testing rates among patients in the study?
So in this study, the one that really came up to the top was race. Black patients really had lower testing rates than White patients or Asian patients, actually. And that is something that we need to understand more why that's happening. And they have higher rates of triple negative breast cancer, so we need to understand more about that.
The other thing that was significant was the type of insurance people had. So the testing rates were higher for people who had private insurance or Medicaid, and it was lower for Medicare and private pay. And so, why is that? And can we affect that piece? This information might help us address some of these.
There were also a few other things that were significant, like the region in which a patient was, and age. There was a small difference in age—I think 4 and a half years between those who were tested and those who were not tested, so younger patients were more likely to get tested.
Can you discuss the overall importance of studying germline genetic testing uptake in the community oncology setting?
Well, first, I think we did not even understand what our testing rate was in the community oncology setting in this population. So it actually took some work to look at medical records, where are things documented, where things weren't documented. So learning that piece was really important, and and I think we learned a lot about where data is. I mean, people get tested before they even come to the oncologist, and does that information come over to the oncologist? So we learned a lot about that—about where it's documented and how to better [it, and] what the best practice is for that. And then, communication with our practices. All of the practices that participated in this study were practices that had a strong genetics program, and they're part of our GREAT network, which stands for genetic risk evaluation and testing. So it's a program a network of genetic providers. And so we have a strong genetic core in those practices, but we learned a lot about that we still need to work on with our with our oncologists and other other providers to make sure that these patients are getting what they need.
Social Determinants of Health Impact Germline Testing Rates Among Patients With TNBC
Rose McNulty
Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study of social determinants of health in the context of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.
Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study she and colleagues conducted to assess the impact of social determinants of health in the context of germline genetic testing for triple-negative breast cancer in the community oncology setting.
Transcript
Which social determinants of health were most impactful on germline genetic testing rates among patients in the study?
So in this study, the one that really came up to the top was race. Black patients really had lower testing rates than White patients or Asian patients, actually. And that is something that we need to understand more why that's happening. And they have higher rates of triple negative breast cancer, so we need to understand more about that.
The other thing that was significant was the type of insurance people had. So the testing rates were higher for people who had private insurance or Medicaid, and it was lower for Medicare and private pay. And so, why is that? And can we affect that piece? This information might help us address some of these.
There were also a few other things that were significant, like the region in which a patient was, and age. There was a small difference in age—I think 4 and a half years between those who were tested and those who were not tested, so younger patients were more likely to get tested.
Can you discuss the overall importance of studying germline genetic testing uptake in the community oncology setting?
Well, first, I think we did not even understand what our testing rate was in the community oncology setting in this population. So it actually took some work to look at medical records, where are things documented, where things weren't documented. So learning that piece was really important, and and I think we learned a lot about where data is. I mean, people get tested before they even come to the oncologist, and does that information come over to the oncologist? So we learned a lot about that—about where it's documented and how to better [it, and] what the best practice is for that. And then, communication with our practices. All of the practices that participated in this study were practices that had a strong genetics program, and they're part of our GREAT network, which stands for genetic risk evaluation and testing. So it's a program a network of genetic providers. And so we have a strong genetic core in those practices, but we learned a lot about that we still need to work on with our with our oncologists and other other providers to make sure that these patients are getting what they need.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
At-Home DMD Video Assessment Found Valid, Reliable
April 18th 2025The remote measurement tool enables Duchenne muscular dystrophy (DMD) assessments through analysis of caregiver-recorded videos.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Elinzanetant Effective for Menopause Symptoms Across BMI, Smoking Status
April 17th 2025Elinzanetant significantly reduced the frequency and severity of vasomotor symptoms, known as hot flashes, compared with placebo across body mass index (BMI) and smoking status subgroups.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
At-Home DMD Video Assessment Found Valid, Reliable
April 18th 2025The remote measurement tool enables Duchenne muscular dystrophy (DMD) assessments through analysis of caregiver-recorded videos.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Elinzanetant Effective for Menopause Symptoms Across BMI, Smoking Status
April 17th 2025Elinzanetant significantly reduced the frequency and severity of vasomotor symptoms, known as hot flashes, compared with placebo across body mass index (BMI) and smoking status subgroups.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More